Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2

被引：0
|
作者：
Feagan, B.
Keininger, D.
Coteur, G.
Schreiber, S.
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] Univ Kiel, Kiel, Germany
[3] SGS Life Sci Serv, Mechelen, Belgium
来源：
INFLAMMATORY BOWEL DISEASES | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：661 / 662
页数：2
相关论文
共 50 条
  • [31] Pharmacovigilance Data on Pregnancy Outcomes in Women With Crohn's Disease Exposed to Certolizumab Pegol
    Clowse, Megan E.
    Dubinsky, Marla C.
    Fischer-Betz, Rebecca
    Nelson-Piercy, Catherine
    Scheuerle, Angela E.
    Stephan, Brigitte
    Kumke, Thomas
    Kasliwal, Rachna
    Lauwerys, Bernard
    Forger, Frauke
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S347 - S348
  • [32] Certolizumab pegol in treatment of Crohn's disease with perianal lesions
    Khalif, I. L.
    Nanaeva, B. A.
    Shapina, M., V
    Vardanyan, A. V.
    TERAPEVTICHESKII ARKHIV, 2018, 90 (04) : 50 - 54
  • [33] Severe Crohn's disease symptoms are relieved by certolizumab pegol
    Feagan, Brian G.
    Coteur, Geoffroy
    Keininger, Doroth L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S471 - S471
  • [34] Certolizumab pegol: A guide to its use in Crohn's disease
    不详
    Drugs & Therapy Perspectives, 2007, 23 (11) : 5 - 8
  • [35] Successful treatment of fistulizing Crohn's disease with certolizumab pegol
    Danese, Silvio
    Stefanelli, Tommaso
    Omodei, Paolo
    Zatelli, Stefania
    Bonifacio, Cristiana
    Balzarini, Luca
    Repici, Alessandro
    Malesci, Alberto
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (02) : 292 - 293
  • [36] The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn's disease
    Schwartz, David A.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 125 - 128
  • [37] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [38] Disease Location as a Risk Determinant for Maintenance of Remission in Crohn's Disease Patients Treated With Certolizumab Pegol: Results of Analyses From the PRECiSE 3 Study
    Schreiber, Stefan
    Randall, Charles
    Dubinsky, Marla
    Kosutic, Gordana
    Pierre-Louis, Bosny
    Spearman, Marshall
    Sandborn, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S513 - S513
  • [39] Serum Certolizumab Pegol Levels and Antibodies to Certolizumab Pegol Are Associated With C-Reactive Protein Levels in Patients With Crohn's Disease
    Yarur, Andres
    Hauenstein, Scott
    Czul, Frank
    Lockton, Steven
    Quintero, Maria
    Barkin, Jamie
    Jain, Anjali
    Singh, Sharat
    Abreu, Maria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S523 - S523
  • [40] Crohn's Disease Behavior as a Risk Factor for Loss of Maintenance of Remission in Patients Treated With Certolizumab Pegol: Results From the PRECiSE 3 Study
    Rubin, David
    Randall, Charles
    Coarse, Jason
    Kosutic, Gordana
    Spearman, Marshall
    Ambarkhane, Sumeet
    Jojic, Njegica
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S508 - S509
12345